slides · global inventory
Title
Component collection for the active corpus filters, with each row opening the slide detail view.
Matching slides 303,780
Current window 204,751-204,780
Pages 10,126
Rows per page 30
Component
204,751-204,780 of 303,780
02
NeuroBo Pharmaceuticals | Securities Offering Presentation Deck | 30 slidesNeuroBo Pharmaceuticals | Securities Offering Presentation Deck | 30 slides · NeuroBo Pharmaceuticals
Regulatory filing Investor relations 1 hit
03
NeuroBo Pharmaceuticals | Securities Offering Presentation Deck | 30 slidesNeuroBo Pharmaceuticals | Securities Offering Presentation Deck | 30 slides · NeuroBo Pharmaceuticals
Regulatory filing Investor relations 1 hit
04
The slide details a strategic partnership involving equity investment and asset licensing.NeuroBo Pharmaceuticals | Securities Offering Presentation Deck | 30 slides · NeuroBo Pharmaceuticals
Regulatory filing Investor relations 1 hit
05
Includes details on upfront payments, private placement, and milestone/royalty structures.NeuroBo Pharmaceuticals | Securities Offering Presentation Deck | 30 slides · NeuroBo Pharmaceuticals
Regulatory filing Investor relations 1 hit
06
The slide uses a Gantt-style visualization to map drug development stages against specific clinical indications and future catalysts.NeuroBo Pharmaceuticals | Securities Offering Presentation Deck | 30 slides · NeuroBo Pharmaceuticals
Regulatory filing Investor relations 1 hit
07
NASH (Non-Alcoholic Steatohepatitis); IND (Investigational New Drug); MAD (Multiple Ascending Dose); SAD (Single Ascending Dose).NeuroBo Pharmaceuticals | Securities Offering Presentation Deck | 30 slides · NeuroBo Pharmaceuticals
Regulatory filing Investor relations 1 hit
08
The slide serves as a title or introductory page for a specific drug candidate.NeuroBo Pharmaceuticals | Securities Offering Presentation Deck | 30 slides · NeuroBo Pharmaceuticals
Regulatory filing Investor relations Beat · SolutionLoop · Quick Win Big Bet1 hit
10
Study methodology involves 10-week treatment on high fat/fructose/CHO diet.NeuroBo Pharmaceuticals | Securities Offering Presentation Deck | 30 slides · NeuroBo Pharmaceuticals
Regulatory filing Investor relations Beat · SolutionLoop · Quick Win Big Bet1 hit
11
Study design timeline included; statistical significance noted for treatment groups.NeuroBo Pharmaceuticals | Securities Offering Presentation Deck | 30 slides · NeuroBo Pharmaceuticals
Regulatory filing Investor relations Beat · SolutionLoop · Quick Win Big Bet1 hit
12
Includes definitions for abbreviations and source citations.NeuroBo Pharmaceuticals | Securities Offering Presentation Deck | 30 slides · NeuroBo Pharmaceuticals
Regulatory filing Investor relations Beat · SolutionLoop · Quick Win Big Bet1 hit
14
Company branding slide for a specific drug candidate.NeuroBo Pharmaceuticals | Securities Offering Presentation Deck | 30 slides · NeuroBo Pharmaceuticals
Regulatory filing Investor relations Beat · SolutionLoop · Quick Win Big Bet1 hit
16
Data from preclinical study in HF-DIO mice.NeuroBo Pharmaceuticals | Securities Offering Presentation Deck | 30 slides · NeuroBo Pharmaceuticals
Regulatory filing Investor relations Beat · SolutionLoop · Quick Win Big Bet1 hit
19
Includes study methodology timeline and statistical significance markers.NeuroBo Pharmaceuticals | Securities Offering Presentation Deck | 30 slides · NeuroBo Pharmaceuticals
Regulatory filing Investor relations Beat · SolutionLoop · Quick Win Big Bet1 hit
20
NASH (Non-Alcoholic Steatohepatitis); MAD (Multiple Ascending Dose); SAD (Single Ascending Dose); PK (Pharmacokinetic); PD (Pharmacodynamic); FPFV (First Patient First Visit); LPLV (Last Patient Last Visit).NeuroBo Pharmaceuticals | Securities Offering Presentation Deck | 30 slides · NeuroBo Pharmaceuticals
Regulatory filing Investor relations Beat · SolutionLoop · Quick Win Big Bet1 hit
21
NeuroBo Pharmaceuticals | Securities Offering Presentation Deck | 30 slidesNeuroBo Pharmaceuticals | Securities Offering Presentation Deck | 30 slides · NeuroBo Pharmaceuticals
Regulatory filing Investor relations 1 hit
22
Includes a bar chart for NASH diagnosis and a funnel diagram for Obesity patient progression.NeuroBo Pharmaceuticals | Securities Offering Presentation Deck | 30 slides · NeuroBo Pharmaceuticals
Regulatory filing Investor relations Beat · ProblemLoop · Cost Of Inaction1 hit
24
The slide highlights rapid adoption compared to Saxenda and notes supply chain issues impacting Q4'21 and H1'22.NeuroBo Pharmaceuticals | Securities Offering Presentation Deck | 30 slides · NeuroBo Pharmaceuticals
Regulatory filing Investor relations 1 hit
25
The slide uses a 'before-after' style comparison to show the potential market cap uplift for NeuroBo's assets compared to current peer valuations.NeuroBo Pharmaceuticals | Securities Offering Presentation Deck | 30 slides · NeuroBo Pharmaceuticals
Regulatory filing Investor relations 1 hit
26
Includes footnotes regarding anti-dilution provisions and Dong-A license agreement terms.NeuroBo Pharmaceuticals | Securities Offering Presentation Deck | 30 slides · NeuroBo Pharmaceuticals
Regulatory filing Investor relations Beat · Financials1 hit
28
The slide details the IP ownership status and patent expiration timelines for two specific drug candidates.NeuroBo Pharmaceuticals | Securities Offering Presentation Deck | 30 slides · NeuroBo Pharmaceuticals
Regulatory filing Investor relations 1 hit
29
NeuroBo Pharmaceuticals | Securities Offering Presentation Deck | 30 slidesNeuroBo Pharmaceuticals | Securities Offering Presentation Deck | 30 slides · NeuroBo Pharmaceuticals
Regulatory filing Investor relations 1 hit
30
NeuroBo Pharmaceuticals | Securities Offering Presentation Deck | 30 slidesNeuroBo Pharmaceuticals | Securities Offering Presentation Deck | 30 slides · NeuroBo Pharmaceuticals
Regulatory filing Investor relations 1 hit
01
Nuvalent | Investor Presentation Deck | 31 slidesNuvalent | Investor Presentation Deck | 31 slides · Nuvalent
Conference presentation Investor relations 1 hit
02
Nuvalent | Investor Presentation Deck | 31 slidesNuvalent | Investor Presentation Deck | 31 slides · Nuvalent
Conference presentation Investor relations 1 hit
03
The slide uses a clean, minimalist layout with a network-style background graphic.Nuvalent | Investor Presentation Deck | 31 slides · Nuvalent
Conference presentation Investor relations 1 hit
05
The slide uses a matrix-like structure to compare drug capabilities against specific clinical requirements.Nuvalent | Investor Presentation Deck | 31 slides · Nuvalent
Conference presentation Investor relations 1 hit
06
The slide uses a human anatomy diagram to map specific TRK receptor inhibition (TRKB, TRKC, TRKA) to associated clinical side effects.Nuvalent | Investor Presentation Deck | 31 slides · Nuvalent
Conference presentation Investor relations Beat · ProblemLoop · Cost Of Inaction1 hit
08
The slide uses dot plots for IC50 values and a bar chart for tumor regression, highlighting NVL-520's performance.Nuvalent | Investor Presentation Deck | 31 slides · Nuvalent
Conference presentation Investor relations Loop · Cost Of Inaction1 hit
09
The chart on the right uses a logarithmic scale for the Selectivity Index.Nuvalent | Investor Presentation Deck | 31 slides · Nuvalent
Conference presentation Investor relations Loop · Cost Of Inaction1 hit
10
Includes list of authors and their institutional affiliations.Nuvalent | Investor Presentation Deck | 31 slides · Nuvalent
Conference presentation Investor relations Loop · Cost Of Inaction1 hit